|

Probiotics in Mild Alzheimer's Disease

RECRUITINGEarly 1Sponsored by University of Nicosia
Actively Recruiting
PhaseEarly 1
SponsorUniversity of Nicosia
Started2022-12-19
Est. completion2025-07-01
Eligibility
Age65 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06181513

Summary

The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).

Eligibility

Age: 65 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adults ≥65 years, able to give consent
* Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
* approximately equal male:female ratio

Exclusion Criteria:

* Inability to give consent
* other neurological disease
* relevant psychiatric disorders (e.g. major depression)
* gastrointestinal/metabolic conditions
* history of alcohol/substance dependence
* use of systemic antibiotics in the previous 6 months
* corticosteroid use
* immune stimulating medications
* immunosuppressive agents
* probiotics consumption in the previous 6 months.
* immunosuppression
* structural heart disease
* neutropenia
* radiation
* active intestinal disease

Conditions3

Alzheimer's DiseaseCognition Disorders in Old AgeNeurodegenerative Diseases

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.